| User's Publication |
|
21868
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Cancer Lett
2024
587:216692
PubMed ID: 38342232
DOI: 10.1016/j.canlet.2024.216692
|
|
19672
Chiou LW, Chan CH, Jhuang YL, Yang CY, Jeng YM.
DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
J Biomed Sci
2023
;30(1):50
PubMed ID: 37386628
DOI: 10.1186/s12929-023-00940-4
|
|
17631
Sabari JK, Velcheti V, Shimizu K, Strickland MR, Heist RS, Singh M, Nayyar N, Giobbie-Hurder A, Digumarthy SR, Gainor JF, Rajan AP, Nieblas-Bedolla E, Burns AC, Hallin J, Olson P, Christensen JG, Kurz SC, Brastianos PK, Wakimoto H.
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Clin Cancer Res
2022
28(15):3318-3328
PubMed ID: 35404402
DOI: 10.1158/1078-0432.CCR-22-0383
|
|
16498
Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M.
Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
Br J Cancer
2022
126(5):744-753
PubMed ID: 34795410
DOI: 10.1038/s41416-021-01629-x
|
|
20913
Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM.
PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.
Br J Cancer
2022
PubMed ID: 36319849
DOI: 10.1038/s41416-022-02032-w
|
|
15499
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T.
A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy
Cancer Sci
2021
112(7):2705-2713
PubMed ID: 34009705
DOI: 10.1111/cas.14973
|
|
12061
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H.
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Cancer Immunol. Immunother.
2020
PubMed ID: 32086539
DOI: 10.1007/s00262-020-02524-9
|
|
13401
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H.
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Oncoimmunology
2020
PubMed ID: 33457076
DOI: 10.1080/2162402X.2020.1856545
|
|
13773
Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites
Cancer Sci
2020
111(2):667-678
PubMed ID: 31828882
DOI: 10.1111/cas.14278
|
|
15895
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG.
The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Cancer Discov
2020
10(1):54-71
PubMed ID: 31658955
DOI: 10.1158/2159-8290.CD-19-1167
|
|
11609
Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H.
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
J Transl Med
2019
PubMed ID: 31221178
DOI: 10.1186/s12967-019-1957-5
|
|
10606
Kanno E, Kawasaki O, Takahashi K, Takano K, Endo T.
DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Exp. Cell Res.
2018
362:111-120
PubMed ID: 29129563
DOI: 10.1016/j.yexcr.2017.11.008
|
|
10922
Shigeaki Umeda et al
Loss of IL-24 expression facilitates invasion in lung adenocarcinoma
Int J Clin Exp Pathol
2017
10:173-185
|
|
12943
Okudela K, Mitsui H, Woo T, Arai H, Suzuki T, Matsumura M, Kojima Y, Umeda S, Tateishi Y, Masuda M, Ohashi K.
Alterations in cathepsin L expression in lung cancers
Pathol Int
2016
66(7):386-92
PubMed ID: 27327955
DOI: 10.1111/pin.12424
|
|
13988
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H.
Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy
Oncoimmunology
2016
5(6):e1169356
PubMed ID: 27471649
DOI: 10.1080/2162402X.2016.1169356
|
|
7462
Tomita T, Ieguchi K, Sawamura T, Maru Y.
Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor.
PLoS ONE
2015
10:e0118835
PubMed ID: 25738827
DOI: 10.1371/journal.pone.0118835
|
|
19029
Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y.
LRRN4 and UPK3B are markers of primary mesothelial cells
PLoS One
2011
6(10):e25391
PubMed ID: 21984916
DOI: 10.1371/journal.pone.0025391
|
|
16553
Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H.
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer
J Transl Med
2011
9:191
PubMed ID: 22053850
DOI: 10.1186/1479-5876-9-191
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
Back
Top
CELL BANK Website